ESSA Pharma Inc. (EPIX)
1.68
0.00 (0.00%)
At close: Mar 03, 2025, 3:59 PM
1.66
-0.90%
After-hours: Mar 03, 2025, 04:00 PM EST
No 1D chart data available
| Bid | 1.65 |
| Market Cap | 74.35M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.13M |
| EPS (ttm) | -0.69 |
| PE Ratio (ttm) | -2.43 |
| Forward PE | -3.96 |
| Analyst | Hold |
| Ask | 1.71 |
| Volume | 118,827 |
| Avg. Volume (20D) | 302,482 |
| Open | 1.68 |
| Previous Close | 1.68 |
| Day's Range | 1.64 - 1.69 |
| 52-Week Range | 1.40 - 9.60 |
| Beta | 1.61 |
About EPIX
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and A...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2015
Employees 35
Stock Exchange NASDAQ
Ticker Symbol EPIX
Website https://www.essapharma.com
Analyst Forecast
According to 3 analyst ratings, the average rating for EPIX stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 19.40% from the latest price.
Buy 0.00%
Hold 100.00%
Sell 0.00%
4 months ago
-73.08%
ESSA Pharma shares are trading lower after the com...
Unlock content with
Pro Subscription
5 months ago
+2.19%
ESSA Pharma shares are trading higher after the company announced it presented data on prostate cancer therapy Masofaniten at ESMO 2024.
